Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathurin Fumery

Showing results (201-210 of 254) with videos related to

Pageof 26
Sort By:
Alimentary Pharmacology & Therapeutics|February 22, 2020
Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patientsConstance Chapuis-Biron, Anne Bourrier, Maria Nachury, et al.
Gastroenterology|February 26, 2026
Uncovering the dynamics of mucosa-associated microbiota in post-operative recurrence of Crohn's diseaseLéonard Dubois, Alexandre Chaussard, Philippe Seksik, et al.
Alimentary Pharmacology & Therapeutics|December 21, 2020
Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort studyPauline Wils, Philippe Seksik, Carmen Stefanescu, et al.
Alimentary Pharmacology & Therapeutics|November 26, 2020
Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAIDDoriane Broussard, Pauline Rivière, Joelle Bonnet, et al.
The American Journal of Gastroenterology|December 14, 2016
Postoperative Complications after Ileocecal Resection in Crohn's Disease: A Prospective Study From the REMIND GroupMathurin Fumery, Philippe Seksik, Claire Auzolle, et al.
Inflammatory Bowel Diseases|February 27, 2016
Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent MalignancyFlorian Poullenot, Philippe Seksik, Laurent Beaugerie, et al.
United European Gastroenterology Journal|October 5, 2024
Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspectiveTommaso Lorenzo Parigi, Virginia Solitano, Alessandro Armuzzi, et al.
Alimentary Pharmacology & Therapeutics|September 9, 2018
Anti-TNF therapy for genital fistulas in female patients with Crohn's disease: a nationwide study from the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID)Guillaume Le Baut, Laurent Peyrin-Biroulet, Guillaume Bouguen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 24, 2015
Detection of Dysplasia or Cancer in 3.5% of Patients With Inflammatory Bowel Disease and Colonic StricturesMathurin Fumery, Guillaume Pineton de Chambrun, Carmen Stefanescu, et al.
The Lancet. Gastroenterology & Hepatology|January 14, 2023
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trialEdouard Louis, Matthieu Resche-Rigon, David Laharie, et al.
Pageof 26

Showing results (201-210 of 254) with videos related to

Sort By:
Pageof 26
Alimentary Pharmacology & Therapeutics|February 22, 2020
Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patientsConstance Chapuis-Biron, Anne Bourrier, Maria Nachury, et al.
Gastroenterology|February 26, 2026
Uncovering the dynamics of mucosa-associated microbiota in post-operative recurrence of Crohn's diseaseLéonard Dubois, Alexandre Chaussard, Philippe Seksik, et al.
Alimentary Pharmacology & Therapeutics|December 21, 2020
Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort studyPauline Wils, Philippe Seksik, Carmen Stefanescu, et al.
Alimentary Pharmacology & Therapeutics|November 26, 2020
Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAIDDoriane Broussard, Pauline Rivière, Joelle Bonnet, et al.
The American Journal of Gastroenterology|December 14, 2016
Postoperative Complications after Ileocecal Resection in Crohn's Disease: A Prospective Study From the REMIND GroupMathurin Fumery, Philippe Seksik, Claire Auzolle, et al.
Inflammatory Bowel Diseases|February 27, 2016
Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent MalignancyFlorian Poullenot, Philippe Seksik, Laurent Beaugerie, et al.
United European Gastroenterology Journal|October 5, 2024
Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspectiveTommaso Lorenzo Parigi, Virginia Solitano, Alessandro Armuzzi, et al.
Alimentary Pharmacology & Therapeutics|September 9, 2018
Anti-TNF therapy for genital fistulas in female patients with Crohn's disease: a nationwide study from the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID)Guillaume Le Baut, Laurent Peyrin-Biroulet, Guillaume Bouguen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 24, 2015
Detection of Dysplasia or Cancer in 3.5% of Patients With Inflammatory Bowel Disease and Colonic StricturesMathurin Fumery, Guillaume Pineton de Chambrun, Carmen Stefanescu, et al.
The Lancet. Gastroenterology & Hepatology|January 14, 2023
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trialEdouard Louis, Matthieu Resche-Rigon, David Laharie, et al.
Pageof 26